Fig. 1: High-density immunophenotyping of AML surface antigen expression identifies AML-associated antigens.

a, Oncoprint summarizing AML patient characteristics, clinical parameters and expression of AML-associated antigens on bone marrow leukemic blasts. ELN, European LeukemiaNet. b, Representative UMAPs comparing control and age-matched AML patient bone marrow samples subjected to 36-parameter phenotyping. Heatmap colors indicate relative surface antigen expression intensity. Red dashed lines indicate unbiased identification of malignant blasts. c, Median fluorescent intensity (MFI) of surface antigen expression on normal bone marrow HSPCs (n = 7 donors) versus AML blasts across patients (n = 46). HSCs (Lin⁻CD34⁺CD45^dimCD90⁺CD38⁻); MPP (Lin⁻CD34⁺CD45^dimCD90⁻CD38⁻); CMP, common myeloid progenitor (Lin⁻CD34⁺CD45RA⁻CD38⁺CD123⁺); GMP, granulocyte–macrophage progenitor (Lin⁻CD34⁺CD45RA⁺CD38⁺CD123⁺); MEP, megakaryocyte–erythroid progenitor (Lin⁻CD34⁺CD45RA⁻CD38⁺CD123⁻); P values are from the Mann–Whitney test: U5 snRNP200 blasts versus HSCs, ***P = 0.0006; blasts versus MPPs, ***P = 0.0001; blasts versus CMPs, **P = 0.0016; blasts versus granulocyte–macrophage progenitors, **P = 0.0068; blasts versus MEPs, ***P = 0.0004; CD47⁺ blasts versus HSCs, ***P = 0.0005; blasts versus MPPs, **P = 0.0022; blasts versus CMPs, *P = 0.0202; blasts versus MEPs, *P = 0.0101; TIM-3⁺ blasts versus HSCs, *P = 0.0275; blasts versus MPPs, **P = 0.0028; blasts versus CMPs, *P = 0.0326. Data are mean ± s.e.m.

Source data